Why the study?
Does a high admission Monocyte to High-Density Lipoprotein Ratio (MHR) predict in-hospital mortality and MACE in STEMI patients undergoing primary PCI?
Does a high admission Monocyte to High-Density Lipoprotein Ratio (MHR) predict in-hospital mortality and MACE in STEMI patients undergoing primary PCI?
High admission MHR serves as an inexpensive and readily available prognostic marker for in-hospital mortality and MACE in STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
May aid in-hospital risk stratification after primary PCI in STEMI; extends observational meta-analyses but leaves practice change open.
A high admission MHR among STEMI patients who underwent primary PCI is associated with a higher in-hospital mortality and MACE. This novel marker can be used as an inexpensive and readily available tool for risk stratification.
No takes yet. Share an insight, caveat, or question.
Villanueva et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: